Cite
Klein M, Lotem M, Peretz T, et al. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer. 2013;2013:828329doi: 10.1155/2013/828329.
Klein, M., Lotem, M., Peretz, T., Zwas, S. T., Mizrachi, S., Liberman, Y., Chisin, R., Schachter, J., Ron, I. G., Iosilevsky, G., Kennedy, J. A., Revskaya, E., de Kater, A. W., Banaga, E., Klutzaritz, V., Friedmann, N., Galun, E., Denardo, G. L., Denardo, S. J., Casadevall, A., Dadachova, E., & Thornton, G. B. (2013). Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. Journal of skin cancer, 2013828329. https://doi.org/10.1155/2013/828329
Klein, M, et al. "Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma." Journal of skin cancer vol. 2013 (2013): 828329. doi: https://doi.org/10.1155/2013/828329
Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, Casadevall A, Dadachova E, Thornton GB. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer. 2013;2013:828329. doi: 10.1155/2013/828329. Epub 2013 Jan 10. PMID: 23365757; PMCID: PMC3556872.
Copy
Download .nbib